SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: GlobeNewswire
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bolt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 14, 2024, Bolt announced in a press release that the Company would “cease further development of trastuzumab imbotolimod (BDC-1001)”, Bolt’s lead asset, “and reduce workforce by approximately 50%”. Following Bolt’s announcement, multiple analysts downgraded the Company’s stock. On this news, Bolt’s stock price fell $00.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTPR Newswire
- Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTPR Newswire
BOLT
Earnings
- 5/14/24 - Beat
BOLT
Sec Filings
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- 6/14/24 - Form 4
- BOLT's page on the SEC website